



## Clinical Development and Challenges in Liver Transplantation for Hepatocellular Carcinoma

Guest Editors:

**Dr. Roeland F. De Wilde**

Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands

**Dr. Wojciech G. Polak**

Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands

**Prof. Dr. Jan N.M. IJzermans**

Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands

Deadline for manuscript submissions:

**16 September 2024**



[mdpi.com/si/180950](https://mdpi.com/si/180950)

### Message from the Guest Editors

Dear Colleagues,

Liver transplantation remains the cornerstone treatment for early-stage hepatocellular carcinoma (HCC), considering the generally excellent recurrence-free survival rates; however, the scarcity of sufficient organs as well as the eligibility criteria for patients to qualify for liver transplantation have been challenges to overcome.

Ideally, criteria for transplantation are based on variables that predict biological behavior in order to select those patients who would benefit the most. Thus, extending the donor pool by living donor programs, alongside the rise in liver perfusion techniques in order to test extended donor grafts, has been implemented.


In this Special Issue of *Cancers*, the clinical development and challenges of liver transplantation for HCC will be addressed by highlighting current developments and challenges with respect to transplant criteria, oncological outcomes, bridging/downstaging, neoadjuvant therapy, and donor pool expansion.

Dr. Roeland F. de Wilde

Dr. Wojciech G. Polak

Prof. Dr. Jan N.M. IJzermans

*Guest Editors*



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)